EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pegzilarginase in Arginase 1 Deficiency: Clinical and Biochemical Effects of Treatment Initiation, Discontinuation and Re-Initiation

Martha Caterina Faraguna iD, Viola Crescitelli, Roberta Pretese iD, Maria Valvassori Bolgè, Vera Marchetti, Giusi Sgroi, Stefania Sala, Silvia Gigante iD, Cristina Bonfanti iD, Adriana Balduzzi, Serena Gasperini iD

Children · 28.04.2026 · 13 (5) · 610

DOI: 10.3390/children13050610 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Children, online erschienen am 28.04.2026. Verfasst von Martha Caterina Faraguna und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Italian Ministry of Health, ‘Ricerca Corrente’ Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Arginase 1 deficiency (ARG1-D) is an ultra-rare urea cycle disorder characterized by hyperargininemia and progressive neurological impairment, including spasticity, loss of motor function, and reduced quality of life. Conventional management based on dietary protein restriction and ammonia scavengers rarely achieves adequate metabolic control or prevents neurological deterioration. Pegzilarginase, a recombinant human arginase 1 enzyme, is the first disease-modifying therapy for ARG1-D.

Methods

We report the first Italian real-world experience with pegzilarginase in three pediatric patients with genetically confirmed ARG1-D enrolled in the phase 3 PEACE trial. Clinical, biochemical, functional, nutritional and quality-of-life data were retrospectively collected over a long-term follow-up (2003–2025). Outcomes were evaluated across three phases: treatment initiation (Start), a 13-month treatment interruption due to trial closure (Stop), and therapy re-initiation through an early access program (Restart).

Results

Pegzilarginase rapidly normalized plasma arginine levels and was associated with improvements in motor function, spasticity, walking endurance, dietary protein tolerance, bone mineral density, and quality of life. During treatment interruption, all patients experienced biochemical worsening and clinical deterioration, including increased spasticity, reduced mobility, and emotional distress. Re-initiation of pegzilarginase restored metabolic control and led to progressive neurological and functional recovery, including partial reversal of long-standing motor deficits.

Conclusions

This real-world experience supports pegzilarginase as a disease-modifying therapy for ARG1-D. Sustained normalization of plasma arginine, rather than subthreshold biochemical control, correlates with functional and neurological improvement and may partially reverse non-lesional metabolic brain injury. Early initiation of pegzilarginase, including in newborn-screened patients, may further modify the natural history of ARG1-D.

Schlagwörter

Stichwörter der Autor:innen

arginase 1 deficiencypegzilarginaseprogressive spasticityrecombinant human arginase 1 enzymeurea cycle disorder

Autor:innen und Institutionen

  • Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.
  • School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.

ORCID-Profile: Martha Caterina Faraguna, Roberta Pretese, Silvia Gigante, Cristina Bonfanti, Serena Gasperini

Förderung

  • Ministero della Salute
  • Italian Ministry of Health, ‘Ricerca Corrente’ Program

Zitieren

APA

Faraguna, M. C., Crescitelli, V., Pretese, R., Bolgè, M. V., Marchetti, V., Sgroi, G., Sala, S., Gigante, S., Bonfanti, C., Balduzzi, A., & Gasperini, S. (2026). Pegzilarginase in Arginase 1 Deficiency: Clinical and Biochemical Effects of Treatment Initiation, Discontinuation and Re-Initiation. Children, 13(5), 610. https://doi.org/10.3390/children13050610

Vancouver

Faraguna MC, Crescitelli V, Pretese R, Bolgè MV, Marchetti V, Sgroi G, et al. Pegzilarginase in Arginase 1 Deficiency: Clinical and Biochemical Effects of Treatment Initiation, Discontinuation and Re-Initiation. Children. 2026;13(5):610. doi:10.3390/children13050610

BibTeX
@article{Faraguna2026,
  author = {Faraguna, Martha Caterina and Crescitelli, Viola and Pretese, Roberta and Bolgè, Maria Valvassori and Marchetti, Vera and Sgroi, Giusi and Sala, Stefania and Gigante, Silvia and Bonfanti, Cristina and Balduzzi, Adriana and Gasperini, Serena},
  title = {Pegzilarginase in Arginase 1 Deficiency: Clinical and Biochemical Effects of Treatment Initiation, Discontinuation and Re-Initiation},
  journal = {Children},
  year = {2026},
  volume = {13},
  number = {5},
  pages = {610},
  doi = {10.3390/children13050610}
}
Kostenlos starten →